Page last updated: 2024-10-24

negative regulation of renin secretion into blood stream

Definition

Target type: biologicalprocess

Any process that stops, prevents or reduces the frequency, rate or extent of renin secretion into blood stream. [GOC:TermGenie]

Negative regulation of renin secretion into the bloodstream is a complex process involving multiple pathways and factors that aim to maintain blood pressure within a healthy range. Renin, a key enzyme in the renin-angiotensin-aldosterone system (RAAS), is produced and released by juxtaglomerular cells in the kidneys. Renin's primary role is to initiate a cascade that ultimately leads to vasoconstriction and sodium retention, thereby increasing blood pressure.

The process of negative regulation of renin secretion involves several key mechanisms:

**1. Baroreceptor Reflex:** Specialized sensory receptors in the walls of blood vessels, particularly the carotid sinus and aortic arch, detect changes in blood pressure. When blood pressure increases, these baroreceptors send signals to the brainstem, which in turn inhibits sympathetic nervous system activity. This reduction in sympathetic tone leads to decreased renin secretion.

**2. Macula Densa Feedback Mechanism:** The macula densa, a specialized group of cells in the distal tubule of the nephron, senses changes in sodium chloride concentration in the tubular fluid. When sodium chloride concentration is high, the macula densa signals to the juxtaglomerular cells to decrease renin release. This mechanism helps to prevent excessive sodium retention and subsequent hypertension.

**3. Atrial Natriuretic Peptide (ANP):** When blood volume and pressure increase, the heart releases ANP. ANP acts directly on juxtaglomerular cells to inhibit renin secretion. ANP also promotes sodium excretion by the kidneys, contributing to blood pressure reduction.

**4. Angiotensin II Feedback Loop:** Angiotensin II, a potent vasoconstrictor produced by the RAAS pathway, acts on the juxtaglomerular cells to inhibit its own production by suppressing renin release. This negative feedback loop helps to prevent excessive vasoconstriction and hypertension.

**5. Other Factors:** Several other factors can influence renin secretion, including potassium levels, circulating catecholamines (such as epinephrine and norepinephrine), and prostaglandins. These factors often interact in complex ways to modulate renin release and maintain blood pressure homeostasis.

In summary, the negative regulation of renin secretion is a crucial mechanism for maintaining blood pressure within a healthy range. This complex process involves multiple feedback loops and signaling pathways that ensure appropriate renin release and prevent excessive vasoconstriction and sodium retention.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Proteinase-activated receptor 1A proteinase-activated receptor 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25116]Homo sapiens (human)

Compounds (15)

CompoundDefinitionClassesRoles
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first sourcechromones;
morpholines;
organochlorine compound
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
ultram2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.aromatic ether;
tertiary alcohol;
tertiary amino compound
omega-n-methylarginineN(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.

omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.
amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
vu0099704VU0099704: an antagonist of protease activated receptor 4 (PAR-4); structure in first source
2-bromo-N-[3-(1-oxopropylamino)phenyl]benzamidebenzamides
2-bromo-N-[3-(1-oxobutylamino)phenyl]benzamidebenzamides
sch 79797quinazolines
morphineMeconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound
anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
tapentadolTapentadol: An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.alkylbenzene
o-demethyltramadolalkylbenzene;
ring assembly
rwj-56110RWJ-56110: a PAR-1 antagonist; structure in first source
vorapaxarvorapaxar : A carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethynyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation.

vorapaxar: has antiplatelet activity; structure in first source
carbamate ester;
lactone;
naphthofuran;
organofluorine compound;
pyridines
cardiovascular drug;
platelet aggregation inhibitor;
protease-activated receptor-1 antagonist
e 5555E 5555: a 2-iminopyridine derivative and platelet aggregation inhibitoraromatic ketone
zstk474ZSTK-474 : A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase.benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
AZ3451benzimidazoles;
benzodioxoles;
nitrile;
organobromine compound;
secondary carboxamide
anti-inflammatory agent;
autophagy inducer;
PAR2 negative allosteric modulator